Phase 3 Oesophageal Cancer Trial, Recruiting NCT06086457 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT06086457
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any gender
  • People who have been diagnosed with squamous cell carcinoma of the esophagus (a specific type of esophageal cancer), confirmed through a tissue or cell sample, at an advanced stage (Stage IVb) with cancer that has spread to no more than 2 other areas of the body (including lymph nodes)
  • People who are generally well enough to carry out daily activities, as measured by a standard medical scoring tool (a score of 0 or 1 on the ECOG scale); people aged 65 and over also need to complete a geriatric health assessment showing good overall health
  • People whose routine blood tests and liver and kidney function results show no significant abnormalities
  • People who have not previously had radiation treatment to the chest area
  • People whose doctors expect them to live for more than 12 weeks
  • People who have given their written informed consent to take part

Who may not be able to join:

  • People who have a history of another type of cancer, except for certain non-invasive or non-melanoma skin cancers, a specific type of throat cancer (hypopharyngeal carcinoma in situ), or cervical carcinoma in situ
  • People who have already had surgery (other than a stoma/ostomy procedure), chemotherapy, or any other cancer treatment before joining the trial
  • People who currently have an active infection, or who have had a heart attack, stroke, or surgery on the stomach, gut, nervous system, heart, or lungs within the 6 months before joining the trial
  • People with a known allergy to chemotherapy drugs, or who have a history of autoimmune disease
  • People who are currently taking part in another clinical trial, or who have done so within the 4 weeks before joining
  • People for whom a radiation oncologist has determined that radiation therapy cannot be safely given — for example, due to a high risk of developing an abnormal opening (fistula) in the body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lin Shen, MD, Peking University Cancer Hospital & Institute

Phone: 8601087787625

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
4 February 2024
Est. completion
28 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov